Sylvia von Mackensen

Sylvia von Mackensen

Auto-generated profile, based on publicly available information

Sylvia von Mackensen

Department of Medical Psychology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2004 in Haemophilia
Verified
Journal Article
Closed access
PDF file
SMS. Von Mackensen
S. Von Mackensen
MBM. Bullinger
M. Bullinger
HGHaemo‐QoL Group
Haemo‐QoL Group

7 August 2007 in Haemophilia
Verified
Journal Article
Closed access
PDF file
SMS. VON Mackensen
S. VON Mackensen

14 November 2018 in Haemophilia
Verified
Journal Article
Closed access
PDF file
JOJohannes Oldenburg
Johannes Oldenburg
JMJohnny Ndoni Mahlangu
Johnny Ndoni Mahlangu
WBWillem Bujan
Willem Bujan
PTPeter Trask
Peter Trask
MCMichael Urban Callaghan
Michael Urban Callaghan
SMSylvia von Mackensen
Sylvia von Mackensen

26 August 2004 in International Journal of Biometeorology
Verified
Journal Article
Closed access
PDF file
SMSylvia von Mackensen
Sylvia von Mackensen
PHPeter Hoeppe
Peter Hoeppe
AMAbdel Maarouf
Abdel Maarouf
PTPierre Tourigny
Pierre Tourigny
DNDennis Nowak
Dennis Nowak

25 June 2021 in Haemophilia
Verified
Journal Article
Open access
PDF file
MSMark Skinner
Mark Skinner
CNClaude Négrier
Claude Négrier
IPIdo Paz‐Priel
Ido Paz‐Priel
SCSammy Chebon
Sammy Chebon
VJVictor Jimenez-Yuste
Victor Jimenez-Yuste
SPSteven W. Pipe
Steven W. Pipe
Introduction: Severe haemophilia A (HA) has a major impact on health‐related quality of life (HRQoL).Aim: Assess the impact of emicizumab on HRQoL in persons with severe HA (PwHA) without factor VIII (FVIII) inhibitors in the phase 3 HAVEN 3 and 4 studies.Methods: This pooled analysis examines the HRQoL of PwHA aged ≥ 18 years treated with emicizumab prophylaxis via Haemophilia‐Specific Quality of Life Questionnaire for Adults (Haem‐A‐QoL) and EuroQoL 5‐Dimensions 5‐levels (EQ‐5D‐5L). In particular, changes from baseline in Haem‐A‐QoL ‘Physical Health’ (PH) domain and ‘Total Score’ (TS) are evaluated.Results: Among 176 evaluable participants, 96 (55%) had received prior episodic treatment and 80 (45%) prophylaxis; 70% had ≥ 1 target joint and 51% had experienced ≥ 9 bleeds in the previous 24 weeks. Mean Haem‐A‐QoL PH and TS improved after emicizumab initiation. Mean (standard deviation) –12.0 (21.26)‐ and –8.6 (12.57)‐point improvements were observed in PH and TS from baseline to Week 73; Week 73 scores were 27.9 (24.54) and 22.0 (14.38), respectively. Fifty‐four percent of participants reported a clinically meaningful improvement in PH scores (≥ 10 points) by Week 73. Subgroups with poorer HRQoL prior to starting emicizumab (i.e. receiving episodic treatment, ≥ 9 bleeds, target joints) had the greatest improvements in PH scores, and corresponding reductions in missed workdays; change was not detected among those previously taking prophylaxis. No change over time was detected by the EQ‐5D‐5L questionnaire.Conclusions: Emicizumab prophylaxis in PwHA without FVIII inhibitors resulted in persistent and meaningful improvements in Haem‐A‐QoL PH and less work disruption than previous treatment.

30 March 2017 in Haemophilia
Verified
Journal Article
Open access
PDF file
SMS. von Mackensen
S. von Mackensen
WKW. Kalnins
W. Kalnins
JKJ. Krucker
J. Krucker
JWJ. Weiss
J. Weiss
WMW. Miesbach
W. Miesbach
JOJ. Oldenburg
J. Oldenburg
Introduction: National Member Organisations (NMO) of persons with haemophilia (PWH) from the DACH Region (D = Germany, A = Austria, CH = Switzerland) were interested to better understand PWH's expectations and concerns of extended half‐life (EHL) factor concentrates (FC) before availability in these countries.Methods: Based on an expert meeting and focus groups conducted across Germany a survey for haemophilia patients and their parents was developed and was sent out to 2,644 PWH.Results: One thousand and seven questionnaires were sent back (38.1%); 743 adults and 262 parents. Most patients had haemophilia A (84.5%), were severely affected (73.7%), received prophylaxis (57%) and used recombinant FC (60.2%). One‐quarter did not know the correct half‐life of their FC [HA/FVIII: 26%, HB/FIX: 31.1%]. Four percent were unsatisfied with their current FC, mainly with short half‐life of FC and difficult manageability. They expected from new EHL products less frequent injections (55.2%), better efficacy (32.1%) and safety/no side effects (15.7%); 59.5% would be willing to switch to new products if they have a prolonged half‐life and the same safety of the current FC. They wish more information about half‐life (84.4%), possible side‐effects (81.3%) and efficacy (77%) and wanted to receive information about new products from their haemophilia treater (76.3%) and the newsletter of their NMO (74.3%). Significant differences across countries were found.Conclusions: The representative survey could show that although PWH were generally satisfied with their current FC, the majority would be willing to switch to EHL products assuming half‐life is prolonged and has the same safety of the current FC.